Every S-3 that Stereotaxis, Inc. (STXS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow STXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STXS filings page.
Stereotaxis, Inc. is registering 108,868,331 shares of common stock for resale by existing investors. The shares consist of up to 72,722,177 shares issuable upon conversion of Series A Convertible Preferred Stock, which carries a 6.0% cumulative dividend paid in stock, and 36,146,154 shares issued upon exercise of related warrants.
The company will not sell any securities or receive proceeds from these resales, having previously raised $24 million in the 2016 preferred-and-warrant financing and approximately $10.0 million plus $0.8 million from warrant exercises. As of June 30, 2026, 97,934,076 common shares were outstanding.
The filing also describes the July 2026 acquisition of French robotics firm Robocath for approximately $20.0 million in cash and stock, plus up to $25.0 million of milestone-based earnout consideration, payable in cash, shares or Purchaser Warrants, subject to a 19.9% share cap. Stereotaxis further highlights potential dilution from preferred stock, earnout shares and a $100.0 million universal shelf with an associated $50 million at-the-market facility.
Stereotaxis, Inc. is registering up to 19,449,603 shares of common stock for resale by Robocath securityholders and Robocath’s financial advisor, including 6,269,628 Closing Shares and up to 13,179,975 Earnout Shares linked to future milestones. Stereotaxis is not selling shares and will receive no resale proceeds, other than de minimis cash if $0.001 Purchaser Warrants are exercised.
The shares stem from the July 7, 2026 acquisition of Robocath, a French robotic-intervention company, completed for approximately $20.0 million in cash and stock plus up to $25.0 million in contingent earnouts. Combined Closing and Earnout Shares are capped at 19.9% of pre‑closing common stock, limiting share issuance but creating potential dilution and resale overhang, partly moderated by volume limits and European Investment Bank priority rights under a Resale Organization Agreement. Stereotaxis designs and sells robotic magnetic navigation systems and related technologies for minimally invasive cardiac and other endovascular procedures.
Stereotaxis, Inc. files a replacement shelf registration that carries forward $79,639,304 of unsold securities under Rule 415(a)(6) as replacement registration for the prior registration declared effective June 6, 2023. The filing establishes a shelf for up to $100,000,000 of securities, including an at-the-market sales agreement previously sized at $50,000,000.
The prospectus states that upon effectiveness the remaining $42,139,304 available under the prior sales agreement will be included in the Sales Agreement prospectus forming part of this registration statement. Shares outstanding were 97,248,936 as of February 28, 2026, provided here as a context figure.